Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Tocilizumab in COVID-19: finding the optimal route and dose

The Lancet Rheumatology - The Tocilizumab in Patients with Severe COVID-19 Pneumonia (TESEO) study by Giovanni Guaraldi and colleagues1 provides vital information regarding the benefits of tocilizumab in severe pneumonia due to COVID-19. However, certain aspects of the study warrant deliberation in greater detail.

Read the full article here

Related Content